GlycoFi Awarded $1M NIH Grant to Aid in the Production of Therapeutic Proteins in Yeast
Wednesday September 24, 9:02 am ET
LEBANON, N.H.--(BUSINESS WIRE)--Sept. 24, 2003--GlycoFi, Inc. announces the award of a Phase II Small Business Innovation Research (SBIR) grant from the National Institutes of Health. The award will support a $1M research project over an 18 month period to further develop GlycoFi's automated, high-throughput approach for the engineering of humanized yeast strains. These strains will be capable of expressing therapeutic proteins with human-like glycosylation structures of unprecedented homogeneity. GlycoFi's technology can be used to produce proteins to address a large spectrum of medical needs.
"This Phase II award will accelerate the development of our human therapeutic protein production platform and build on the achievements of Phase I," said Chief Scientific Officer Tillman Gerngross.
About GlycoFi
GlycoFi, Inc., privately held, was founded in 2000 with the mission of dramatically improving the capacity and cost of producing human therapeutic proteins, while simultaneously enhancing their efficacy and safety as therapeutics. The company harnesses the inherent advantages of yeast and other fungal-based protein expression systems by engineering these systems to produce correctly glycosylated human therapeutic proteins, thus greatly increasing the efficiency, fidelity and scalability at which those proteins can be made. For more information on GlycoFi, please visit the company's website at www.glycofi.com. |
